Abstract
While HIV kills most of the cells it infects, a small number of infected cells survive and become latent viral reservoirs, posing a significant barrier to HIV eradication. However, the mechanism by which immune cells resist HIV-induced apoptosis is still incompletely understood. Here, we demonstrate that while acute HIV infection of human microglia/macrophages results in massive apoptosis, a small population of HIV-infected cells survive infection, silence viral replication, and can reactivate viral production upon specific treatments. We also found that HIV fusion inhibitors intended for use as antiretroviral therapies extended the survival of HIV-infected macrophages. Analysis of the pro- and anti-apoptotic pathways indicated no significant changes in Bcl-2, Mcl-1, Bak, Bax or caspase activation, suggesting that HIV blocks a very early step of apoptosis. Interestingly, Bim, a highly pro-apoptotic negative regulator of Bcl-2, was upregulated and recruited into the mitochondria in latently HIV-infected macrophages both in vitro and in vivo. Together, these results demonstrate that macrophages/microglia act as HIV reservoirs and utilize a novel mechanism to prevent HIV-induced apoptosis. Furthermore, they also suggest that Bim recruitment to mitochondria could be used as a biomarker of viral reservoirs in vivo.
Introduction
A major challenge to eradicate HIV is the formation of long-lasting HIV reservoirs that are resistant to antiretroviral therapy (ART). The best recognized and examined viral reservoir corresponds to different CD4+ T cell populations, including naïve and memory CD4+ T cells. Infection of both populations has been extensively reported in HIV-infected individuals1. It is believed that this pool of HIV-infected cells corresponds to <0.05% of circulating cells during asymptomatic infection under effective ART2.
It is widely accepted that monocyte/macrophage lineage cells are among the first cells targeted by HIV3, and that these cells then allow the virus to spread rapidly by transmission to CD4+ T cells4–6. Macrophages are terminally differentiated, non-dividing cells derived from circulating monocytes and reside in various tissues, where they are referred to by different names, such as perivascular or alveolar macrophages, Kupffer’s cells in the liver, or microglia in the brain7. Under inflammatory conditions, macrophages derived from recently transmigrated monocytes die after few days8, whereas microglia, perivascular, and alveolar macrophages can survive for long periods – from weeks to years9–11. The properties of mobility, capacity for tissue infiltration, and extended survival have been proposed by several groups to be critical for the role of macrophages in the generation, stability, dissemination, and reactivation of HIV reservoirs. Furthermore, it has been demonstrated that macrophages alone can sustain HIV replication in vivo, supporting the hypothesis that macrophages are a primary target of HIV and may help transmit the infection to other cell types12,13. Nevertheless, the role of monocyte/macrophages as HIV reservoirs has been largely ignored.
Although HIV infection kills most CD4+ T cells, infected macrophages survive for extended periods by harboring the virus in cell membrane invaginations that protect virions from antiretroviral treatment (ART) and circulating neutralizing antibodies14–16. To understand how HIV promotes survival of some infected cells that ultimately become viral reservoirs, several mechanisms of HIV-mediated effects on apoptotic pathways have been examined. Several studies have demonstrated the effects of viral proteins on apoptotic protein expression including Bcl-2, Bax, FLICE inhibitory protein (cFLIP) and X-linked inhibitor of apoptosis (XIAP)17,18. However, most of these studies have been performed in primary and T-cell lines, while the mechanisms of extended survival and viral transmission by HIV-infected macrophages are still unknown.
Here we demonstrate that HIV-infected human microglia and macrophages function as viral reservoirs. We show that these cells survive HIV infection for extended periods of time by avoiding apoptosis and serving as long lasting viral reservoirs. We also identify that accumulation of Bim in the mitochondria of surviving HIV-infected cells does not result in apoptosis and that Bim in the mitochondria could be used as a biomarker of viral reservoirs in vitro and in vivo.
Results
HIV infects and induces apoptosis in human microglia, but a small population of HIV-infected microglia survives the infection
To understand the dynamics of apoptosis in HIV-infected microglia, human fetal microglia were isolated, infected with HIVADA, and stained with DAPI, TUNEL and HIV-p24 to quantify survival of uninfected and HIV-infected cells for up to 120 days. Uninfected cultures of human microglia underwent sustained apoptosis after 21 days in culture (Fig. 1A). HIV infection of microglial cultures resulted in faster initial apoptosis as compared to uninfected cultures up to 21 days (Fig. 1A, *p ≤ 0.007). However, after 21 days post infection, survival of microglial cultures remained stable and higher than uninfected cultures (Fig. 1A, *p ≤ 1.3 × 10−4). To determine whether uninfected or HIV-infected cells were surviving HIV infection, staining for DAPI (to observe the nuclei), phalloidin (to observe the shape of the cells), and HIV-p24 (to detect HIV infection) was performed using staining and subsequent microscopy analysis. The results showed that most surviving microglia in the HIV-infected cultures were HIV-p24 positive (Fig. 1A, 95.27 ± 4.68%) and corresponded to multinucleated cells (82.84 ± 20.09%), indicating HIV infection protects a small population of HIV-infected microglia from apoptosis.
Surviving HIV-infected microglia become latently infected
To examine the dynamics of HIV replication within the infected microglia, we measured levels of HIV-p24 in culture supernatants by ELISA. HIV replication reached a plateau between 28 to 36 days post infection and then decayed to undetectable levels after 120 days post-infection (Fig. 1B). Although the medium was concentrated ten times using Amicon filters (50 kDa, EMD Millipore, Germany), no secreted HIV-p24 was detected by ELISA at 120 days suggesting that viral replication becomes silent (data not shown).
Analysis of the surviving cells by microscopy and FACS indicates that they maintain their macrophage phenotype including iba-1, CD14, CD68, CD11b/c, CD163, and CSF1R expression as well as their phagocytic function, cytokine secretion (TNF-α, IL-1β, and IL-6), and migratory properties in response to CCL2 as described (19–22 and data not shown). In conclusion, all surviving cells correspond to macrophages or microglia, are infected with HIV, and become latently infected.
Latently HIV-infected microglia can be induced to reactivate viral replication
Critical features of viral reservoirs are extended survival, “hiding” the virus by suppressing viral replication and having the capability of reactivating the virus and spreading it to other cells12,23–27. To demonstrate that surviving HIV-infected microglia are latently infected, we induced HIV reactivation after 120-150 days post infection, when no HIV-p24 production is detected, using several factors known to be involved in CNS and peripheral HIV reactivation12,24. Next, we evaluated HIV replication by quantifying HIV-p24 secretion into the tissue culture medium for additional 21 days post treatment (Fig. 1C). Surviving latently HIV-infected microglia were treated with SAHA (N-hydroxy-N′-phenyl-octanediamide, suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, 1 and 10 ng/ml), PHA (1 µg/ml), DKK1 (10 and 100 ng/ml), IL-1β (10 U/ml), methamphetamine (1 µM, Meth), LPS (1 µg/ml) or TNF-α (10 ng/ml) and/or IFN-γ (1 ng/ml). DKK1, IFN-γ and IL-1β did not reactivate viral replication (data not shown). However, SAHA, PHA, Meth, LPS and the combination of TNF-α and IFN-γ induced significant viral reactivation (Fig. 1C). In conclusion, the small microglial population that survives acute HIV infection and silences HIV replication can be induced to reactivate the virus upon specific treatments. Thus, these surviving cells fit the criteria of HIV reservoirs.
HIV integrates into the host DNA, produces viral mRNA, replicates, and spreads among human macrophages
Due to the limited numbers of microglia isolated from brain tissue, subsequent experiments were performed using human macrophages. Despite the various manuscripts demonstrating active HIV infection and replication in macrophages13,28–34, it is still considered controversial that macrophages become infected by HIV mainly because macrophages can store cell-free virions within plasma membrane invaginations for at least a month15,35–38. Thus, to clarify whether macrophages are truly HIV infected, we analyzed HIV integration by multiple techniques, including fluorescent in situ hybridization (FISH) in combination with immunofluorescence, Alu-PCR, mRNA and HIV protein staining, as well as measurements of cell to cell dissemination at different time points (0, 7, 14, 21 and 28 days post-infection).
Using FISH in combination with immunofluorescence, we detected HIV-DNA Nef integration into the host DNA only in HIV infected cultures as early as 24 h post infection and up to 21 days post-infection (Fig. 2A, HIV), where viral replication became undetectable (Fig. 2E). No HIV-DNA Nef staining was detected in uninfected macrophages; only Alu repeats, DAPI and actin showed strong signals as expected (Fig. 2A, Control). These cultures were 99–100% positive for the macrophage marker Iba-1, indicating no T cell contamination (data not shown). Alu-gag PCR confirmed HIV integration into the host DNA after 7 days post infection (Fig. 2B). Furthermore, analysis of viral RNA expression using RNAscope indicated that HIV gag mRNA was produced in macrophages during the entire time course, while no HIV gag mRNA was detected in uninfected cultures (Fig. 2C) or using a scrambled probe (data not shown). We also analyzed the intracellular expression of HIV protein p24 (HIV-p24), by cell immunostaining and by ELISA of the culture supernatant (Fig. 2D and E, respectively). HIV infection of macrophages induced the expression and release of HIV-p24 in a time-dependent manner (Fig. 2D and E, p ≤ 0.0001, n = 3). The increase in HIV-p24 in the culture supernatant from 7 to 14 days post infection confirmed that HIV infection of macrophages was productive. After 14 days HIV replication decreased indicating that some of the HIV-infected macrophages become latently infected (Fig. 2E). Furthermore, HIV was disseminated in a time-dependent manner: the first cycles of replication only infected 8.2 to 32% of all cells (Fig. 2F, 15.69 ± 12.75%) but after 21 days post infection 100% of the cells were infected (Fig. 2F, *p ≤ 0.0001, n = 3) but HIV replication was undetected (Fig. 2E). Together, these data indicate that HIV efficiently integrates into macrophage DNA, produces viral mRNA, and expresses HIV proteins. Furthermore, the increase in HIV-p24 production in the culture supernatant, as well as the spread of infection over 21 days post infection, indicate that macrophages are productively infected upon exposure to HIV. But also our data demonstrate, like microglia, macrophages become latently infected after 21 days post infection despite that 100% of the cells have integrated HIV DNA.
HIV infection of human primary macrophages results in massive apoptosis, but a small population of HIV-infected cells survives the infection
To determine whether HIV infection results in survival of some HIV-infected macrophages; cells were stained for nuclei (DAPI staining), actin (phalloidin staining), and TUNEL at different time points (0 to 21 days post infection) and we quantified the numbers of cells in 10 different fields using microscopy. Cultures of uninfected macrophages showed low levels of apoptosis up to 21 days in culture in a similar manner compared with primary microglial cultures. HIV infection of macrophage cultures resulted in a significant decrease in the total number of macrophages in the cultures, as compared to uninfected cultures (Fig. 3B, p ≤ 2.14 × 10−7, n = 3). A small but stable population of macrophages survived infection up to 21 days (the last point assayed; Fig. 3C). Most of the surviving cells were positive for HIV-p24 and contained HIV integrated DNA as well as showed clear signs of cell to cell fusion (Fig. 3D, HIV). HIV-infected fused macrophages have been described in vitro and in vivo, but not examined in detail, in multiple tissues even during the ART era39–43. In conclusion, these data indicate that similar to HIV-infected microglia, a small population of HIV-infected macrophages survive acute infection and become latently infected.
Surviving fused HIV-infected macrophages are generated by the cell to cell fusion
Currently, they are at least four different mechanisms of multinucleation described in different diseases. First, it has been proposed that cell-to-cell fusion is not truly a result of fusion but instead correspond to phagocytosis of damaged cells40,44. The second mechanism is due to incomplete mitosis40,45; however, macrophages are terminally differentiated and do not divide. Third, cell to cell fusion by mechanisms involving IL-4, CD44, SIRP-α, macrophages fusion receptor (MFR)46,47 and P2X7 (see review by48). Fourth, a mechanism of HIV-induced cell fusion has between proposed involving gp120, gp41, CCR5, and CD449 (Fig. 4A).
To test the third mechanism, we used oxidized ATP (oATP, 100 µM) to block purinergic receptors including P2X7, and probenecid (500 µM) to block pannexin and connexin hemichannels that control the release of ATP into the extracellular medium. We found that neither of these inhibitors altered cell to cell fusion in response to HIV infection (data not shown), suggesting that cell to cell fusion in HIV-infected condition is by an alternative mechanism. To determine whether the presence of multinucleated cells was the result of fusion or phagocytosis, live cell imaging of uninfected and HIV-infected cultures of macrophages was performed. No cell to cell fusion was detected in uninfected cultures (data not shown). However, exposure of macrophage cultures to HIV resulted in the significant cell-to-cell fusion as early as 2-3 days post-infection (Fig. 4B, 3 days post infection and 30 min of live cell imaging, see * and #). In contrast, using live cell imaging, no phagocytosis was detected in uninfected or HIV-infected conditions (data not shown). To further determine whether cell to cell fusion was present in our HIV-infected cultures, scanning electron microscopy of macrophages in the process of fusion was performed (Fig. 4C, inset). Our data indicate a clear continuous membrane between the two cells in the process of fusion (Fig. 4C, arrow). Together these data suggest that the generation of multinucleated cells in response to HIV infection was a product of cell to cell fusion and not an artifact of phagocytosis, ATP-mediated cell-to-cell fusion or incomplete mitosis.
HIV fusion inhibitors decreased HIV replication but increased the survival of HIV-infected macrophages
To examine whether interaction between HIV-infected cells and host receptors (CD4 and CCR5) involved in cell to cell fusion participates in the survival of HIV-infected macrophages, cultures were infected with HIV for 24–48 hours to enable successful HIV integration and replication and then treated with HIV fusion blockers T20 (1 µg/mL) or TAK779 (1 µg/mL). While cell to cell fusion was not altered at any time point in the HIV-infected macrophage cultures treated with TAK779 and T20, we did observe a significant (∼99%) decrease in HIV replication (Fig. 5A). Furthermore, TAK779 and T20 treatment of HIV-infected cultures resulted in a higher numbers of HIV-infected surviving macrophages after 21 days post infection, suggesting that these fusion inhibitors increased the survival of the infected cells (Fig. 5B). TAK779 and T20 treatment also protected non-multinucleated cells present in the HIV-infected cultures from apoptosis (Fig. 5C). Microscopy analysis of the surviving cells in the HIV-infected cultures treated with TAK779 at 21 days indicates that fusion was still present, and most cells had undetectable to minimal HIV-p24 staining (Fig. 5D, HIV + TAK-21 days, compare to Fig. 3D). These results indicate that after initial infection and replication, antiretrovirals such as TAK779 and/or T20 extended the survival of latently infected cells. In conclusion, multinucleation was independent of viral production after initial infection, and HIV fusion inhibitors had an unexpected protective effect on the survival of infected macrophages.
HIV-infected macrophages are protected from HIV-associated apoptosis
A key event in apoptosis is the formation of the transition pore in the mitochondrial membrane and the release of mitochondrial factors, such as cytochrome C, into the cytoplasm50,51. We have reported that HIV infection of human astrocytes results in bystander apoptosis of uninfected neighboring cells by a mechanism that involves the release of cytochrome C (CytC) into the cytoplasm52,53. CytC does not induce apoptosis in the infected astrocytes, but the spread of IP3 and calcium signals through gap junction channels causing apoptosis of uninfected neighbor cells52,53. It is well established that the equilibrium between expression, protein-protein interaction, and formation of the transition pore by pro-apoptotic and anti-apoptotic proteins determines the apoptotic fate of the cell54–56. For instance, anti-apoptotic Bcl2 protein promotes maintaining mitochondrial outer membrane pore integrity by sequestering pro-apoptotic proteins that participate in pore opening57. T cell lines engineered to overexpress Bcl2 have been used as a model to study latency and reactivation58. However, primary cells that survive infection with clinically relevant strains of HIV have never been found to contain elevated levels of Bcl259–61 and if these mechanisms operate in surviving HIV-infected macrophages is unknown.
Here we analyzed the expression of proteins involved in mitochondrial outer membrane (MOM) pore integrity and Cytochrome C-mediated apoptosis, mitochondrial fusion, and apoptosome formation including Bcl-2, Bak, Bax, Bim, mfn-1, XIAP, apaf-1, mcl-1, hsp70, mfn2, hsp27, AIF, and caspase -3 and -9. No changes in protein levels or protein cleavage of these protein was detected (data not shown and Fig. 6A). The only protein affected was Bim. We found that only Bim expression was upregulated in HIV-infected macrophage cultures after 21 days post-infection, or the time when only a few latently HIV-infected macrophages remain in culture (Fig. 6A and B). In contrast, Bim expression was stable in uninfected cultures (Fig. 6B). Also, no changes in the three Bim isoforms (EL, L, and S) were detected in our cultured macrophages (data not shown) aside of the overall increased expression. These multiple Bim isoforms are generated by alternative splicing and have been proposed to have different functions62. Thus, trafficking of the protein into the mitochondria or protein-protein interaction with other apoptotic proteins may be affected. Because Bim is a highly pro-apoptotic protein63, the observation that Bim expression was increased in the few surviving HIV-infected macrophages (Fig. 6B) suggests that Bim may have an alternative function in these cells or HIV blocks its apoptotic function.
HIV prevents initiation of apoptosis and formation of the apoptosome
To examine the mechanisms by which HIV prevents apoptosis in a small population of HIV-infected macrophages, we examined protein expression levels of Apaf-1, CytC, and caspase-3. We detected no changes in expression or activation of caspase-3 in response to HIV infection and no changes in the molecular weights of apoptotic proteins that would result from caspase-mediated cleavage or complex formation with other proteins (Fig. 6C). Also, to identify whether apoptosis-inducing factor (AIF) or cytochrome C are released from the mitochondria into the cytoplasm, cell fractionation was performed in uninfected, and HIV-infected macrophages after 21 days post infection. Our results indicate that AIF and CytC are retained inside of the mitochondria (Fig. 6D). Thus, the apoptotic process is blocked. Finally, to determine whether the mitochondria of the surviving HIV-infected macrophages are functional, we used mitotracker, a membrane potential-sensitive dye. No changes in mitochondrial membrane potential were detected in the surviving HIV-infected macrophages as compared to uninfected cells, indicating that mitochondria are still functional (data not shown). Together, these results indicate that apoptosis is not initiated in HIV-infected macrophages that survive acute HIV infection.
Increased Bim mitochondrial association in HIV-infected macrophages and microglia in vitro and in vivo
Bim is a highly pro-apoptotic protein in most cell types63 that is nevertheless highly upregulated in surviving HIV-infected macrophages where apoptosis is blocked (Fig. 6B). Normally Bim associates with the cytoskeleton, but upon apoptosis activation, Bim is recruited into the mitochondrial membrane to trigger apoptosis64. Using cell fractionation experiments, we determined that bim was also recruited or sequestered into the mitochondria specifically in surviving latently HIV-infected macrophages (Fig. 6D, mito fraction, HIV+). To examine whether Bim also associated with mitochondria in vivo, we used human tissues (lymph nodes and brains) obtained from uninfected and HIV-infected individuals without detectable viral replication and performed immunostaining for Bim, VDAC (a mitochondrial protein), HIV-p24, and DAPI.
As expected, analysis of uninfected lymph nodes and brains showed no staining for HIV-p24 protein (Fig. 7, control-LN and control brain, A and C). Furthermore, in uninfected tissues diffuse Bim and VDAC staining was observed in lymph nodes (Fig. 7A) and brains (Fig. 7C). In contrast, in HIV-infected tissues obtained from individuals on effective ART at the time of death (6-24 years of AR treatment), a few low expressing HIV-p24 infected cells were detected (Fig. 7, HIV-LN and HIV-brain, B and C). These infected cells showed increased expression of Bim in perfect colocalization with VDAC, a mitochondrial protein (Fig. 7B and D), consistent with our in vitro data indicating Bim accumulates in mitochondria of HIV-infected cells in vivo. Our results, in vivo, show that both T cells and macrophages have a similar profile of low expression of HIV proteins and Bim recruited into mitochondria (1 positive cell in 108 to 1012 cells analyzed). Thus, both cell types have a similar profile of Bim. Negative controls using IgGs and control sera did not show any staining (data not shown). Together, these data indicate that Bim expression is increased and it is recruited to the mitochondria in surviving HIV-infected macrophages/microglia, suggesting that Bim may be used as a biomarker to identify HIV reservoirs in vivo.
Discussion
The data presented here demonstrate that a small population of human microglia and macrophages survive acute HIV infection, that these surviving cells are HIV-infected but protected from apoptosis, and that HIV replication is silenced but can be reactivated in these cells. This indicates that these cells act as viral reservoirs. We found that formation of these reservoirs is associated with macrophage fusion and that cell fusion inhibitors extend the survival of HIV-infected cells. Furthermore, we found that while apoptosis is blocked at an early step, the proapoptotic protein Bim is upregulated and recruited into the mitochondria in latently infected macrophages both in vitro and in vivo. Thus, we propose that Bim association with the mitochondria is a potential biomarker of latently HIV-infected macrophages/microglia in vivo.
The presence of fused macrophages, also known as multinucleated giant cells (MNGC), has been reported extensively in the context of AIDS65. Furthermore, several studies of non-AIDS conditions indicate the presence of fused cells in lymphoid organs66–71, HIV-associated lymphoepithelial cysts of the parotid gland71, and colonic mucosa72. Thus, these fused cells are present in vivo, even during effective ART, and are found in virally advantageous regions that are part of or are in close contact with lymphoid areas that can support viral reservoirs and reactivation.
Also, we found that HIV fusion inhibitors T20 and TAK779 unexpectedly resulted in extended survival of a subpopulation of uninfected and HIV-infected macrophages, probably due to the reduction in HIV replication (Fig. 2E). These results indicate that some kinds of ART, i.e. those that prevent cell fusion, may extend the survival of HIV reservoirs by avoiding the toxic effects of high replication. Our hypothesis involves two different mechanisms of cell protection induced by TAK779 and T20. First, a protective effect of these antiviral drugs in latently HIV-infected cells mediated by prevention of cell death of HIV-infected cells as described in the results, but there may be a second mechanism of cell protection of uninfected cells, by preventing binding of the virus to CD4 and CCR5. A similar mechanism of cell death protection mediated by CCR5 has been described in several cell types73–76. This point requires further exploration because this indicates that some ART may have negative effects on the survival of HIV reservoirs.
Although the HIV genome does not encode any apoptosis inhibitor proteins, several HIV proteins such as Tat can upregulate host anti-apoptotic proteins including Bcl-2, FLIP, XIAP and C-IAP277–80. Also, HIV-Nef induces phosphorylation and inactivation of Bad, suggesting that alterations in the apoptotic process contribute to the survival of HIV-infected T cells81. However, we did not detect changes in expression of these apoptotic proteins in our latently HIV-infected macrophages. However, we cannot discard changes in protein-protein interactions, conformational changes, post-transcriptional modifications, or activity of the transition pore on the mitochondria altered by HIV infection. These studies will be the focus of future research. However, several laboratories have identified that the formation of transition pore is affected in other cell types, because overexpression or antagonist of Bcl-2 can control HIV replication, reactivation, susceptibility to apoptosis, but the mechanism is unclear82–86.
Also, our previous studies of human astrocytes indicate that in infected astrocytes the transition pore in the mitochondrial membrane is formed, and CytC is secreted from the mitochondria into the cytoplasm. HIV, however, blocks the subsequent formation of the apoptosome87–90. In contrast, we did not detect any evidence for the formation of the transition pore or secretion of mitochondrial factors into the cytoplasm in latently infected macrophages, indicating that HIV blocks formation or the function of the transition pore early during the apoptotic process. Thus, the mechanism of how HIV promotes the survival of HIV- infected microglia and macrophages is different from those operating in T cells and astrocytes.
A unique feature of surviving latently infected macrophages is the significant upregulation and recruitment of proapoptotic protein Bim into the mitochondria (Fig. 6B). Bim downregulation in cancer cells is related to extended survival, metastasis and improved response to cytotoxic agents (reviewed in91,92). We propose that upregulation and sequestration of Bim into the mitochondria in surviving infected macrophages reflects an early step in the apoptotic pathway, which is subsequently blocked by HIV because Bim recruitment is not associated with apoptosome formation, secretion of CytC or AIF into the cytoplasm, or activation of caspases. The upregulation of Bim is currently used as a promising cancer therapeutic because upregulation of this protein can result in apoptosis63. However, in latently HIV infected cells in vitro and in vivo, Bim did not lead to apoptosis despite its recruitment into the mitochondria. Also, as indicated in the result section, there are no changes in expression or ratios the three different isoforms of Bim. Thus, the mechanism by which Bim is blocking apoptosis of latently HIV-infected macrophages could be related to changes in host protein-protein interaction, the opening of the transition pore, or direct binding of HIV proteins to the pore. Clearly, HIV is altering mitochondrial function/signaling/metabolism93,94, but the interplay between metabolism, survival and viral silencing/reactivation is totally unknown and currently is under active investigation in several laboratories.
An additional explanation of the role of Bim in the surviving HIV infected macrophages is its participation in the metabolism of viral reservoirs. Survival of HIV infected macrophages results in mitochondrial fusion and changes in cell metabolism to promote survival of these cells including the use of alternative sources of fuel such as amino acids. Thus, we propose that bim plays a role in metabolic regulation of the survival of these infected cells. Interesting, Bim during the formation of the transition pore also can interact indirectly with enzymes involved in mitochondrial metabolism such as creatine kinase, and hexokinase95. Furthermore, both enzymes participate in HIV replication and viral reservoir formation93,96, but whether both set of proteins could regulate HIV reservoir metabolism is still under active investigation.
In summary, we have obtained compelling evidence that macrophages/microglia function as HIV reservoirs, and that these viral reservoirs are formed by a novel mechanism involving Bim upregulation and recruitment to mitochondria, which may be useful as a biomarker of viral reservoirs in vivo. These insights, together with the observation that fusion inhibitors increase the size of the latently HIV-infected macrophage pools, need to be incorporated into the current HIV reservoir paradigms and considered during the ongoing efforts to achieve HIV eradication.
Materials and Methods
Reagents
All reagents were purchased from Sigma (St. Louis, MO) except in the places that are indicated otherwise. HIVADA, TAK779, T20, soluble CD4 (sCD4), were from the NIH AIDS Research and Reference Reagent Program (Germantown, MD). Primers and probes were obtained from Biosynthesis (Lewisville, TX) and PNAbio (Newbury Park, CA). Medium, penicillin/streptomycin (P/S), dyes and secondary antibodies were obtained from Thermo-Fisher (Waltham, MA). Human AB serum and FBS were from Lonza (Walkersville, MD). HEPES was from USB (Cleveland, OH). HIV-p24 ELISA was obtained from Perkin-Elmer (Waltham, MA). Antibodies to HIV-p24 were obtained from Genetex (Irvine, CA). All other antibodies were purchased from Sigma, Santa Cruz (Santa Cruz, CA) or Abcam (Cambridge, MA). Purified mouse IgG2B and IgG1 myeloma protein were from Cappel Pharmaceuticals, Inc. TUNEL was obtained from Roche Ltd (Germany). All experiments were performed under the regulations of Rutgers University and the NIH.
Microglia isolation
Human fetal CNS tissue was used as part of an ongoing research protocol approved by Rutgers University (IRB protocols Pro2012001303 and Pro20140000794). Microglia was established as previously described97. Briefly, the tissue was minced and shaken. The slurry was passed through a 250 µm nylon mesh filter followed by a 150 µm filter, washed once with HBSS, and then with complete DMEM (DMEM plus 25 mM HEPES, 10% FCS, 1% penicillin-streptomycin, 1% non-essential amino acids). Cells were resuspended and seeded at 9 × 107 per 150 cm2 flask for 12 days. The medium, containing microglia, was then removed and centrifuged for 5 minutes at 220 × g. The microglia was resuspended in complete DMEM and seeded according to the experiment required. Microglia were infected with HIV and medium was collected every 3 days to measure HIV replication. All experiments performed in microglia were determining HIV-replication as determined by ELISA and apoptosis or survival as determined by microscopy. The main limitation of these cultures is the numbers of microglia.
Monocyte isolation and macrophage culture
Human monocytes were isolated from leukopaks obtained from the New York Blood Center. Peripheral blood mononuclear cells (PBMCs) were isolated by differential centrifugation using a Ficoll gradient (GE Healthcare, Piscataway, NJ). Adherent cells were cultured for 7 days in the presence of 10 ng/ml macrophage colony stimulating factor (Miltenyl Biotec, San Diego, CA) in RPMI 1640 with 10% FBS, 5% human AB serum, 1% P/S, and ten mM HEPES to differentiate the cells into macrophages.
HIV infection and replication
After seven days in culture to enable differentiation, macrophages were inoculated with 20–50 ng/ml HIVADA for 24 hours, and then apoptosis, fusion, and expression of apoptotic proteins was examined. Supernatants were collected, and the medium was changed every 24 hours until 7, 14, 21 and 28 days post-inoculation. Viral replication was analyzed by HIV p24 ELISA according to the manufacturer’s instructions.
Live cell imaging
To assess fusion, macrophages were imaged using a Zeiss AxioObserver Z1 with an LD Plan-Neofluar 5X/0.4 10x air objective lens and a Zeiss AxioCam MRm camera using Axiovision software. Stage and objectives were housed within an incubation chamber maintained at 37 °C and 5% CO2.
HIV integration by fluorescent in situ hybridization (FISH)
Uninfected and HIV-infected macrophages were placed in an ultra-clean glass and incubated in probes directed to HIV-Nef DNA, and Alu repeats as well as immunofluorescence for Iba-1, a macrophage marker, and actin as well as DAPI to label all the nuclei. The resolution of our equipment corresponds to 20 nm per pixel. Thus, colocalization of DAPI, HIV-Nef DNA, and DNA-Alu correspond to integrated HIV DNA. This staining method enables us to detect few copies (even a single copy of HIV integrated DNA) of integrated DNA in the host DNA, however, in this manuscript we did not quantify copy numbers, we only quantified negative versus positive cells. Thus, we expect perfect colocalization between DAPI, Alu repeats, and the HIV integrated DNA is HIV DNA is inserted into the host DNA.
Alu-gag PCR
Integration of HIV into the host genome was detected by Alu-gag PCR as described previously with minor variations98. The system was calibrated using OM-10 cells and diluted OM-10 cells into millions of uninfected Hela cells to quantify the lowest numbers of copies possible in 108 to 1012 cells.
In situ Gag RNA analysis
To examine the formation and localization of gag mRNA, RNAscope was used (Newark, CA). However, we analyzed the data using fluorescence because localization of the RNA is more informative than by colorimetric analysis. We used the same protocol described by the provider in combination with immunofluorescence to detect DAPI (to label nuclei) and Iba-1 (a macrophage marker) in the same cell.
Immunofluorescence
Human macrophages, HIV-infected and uninfected, were grown on glass coverslips, fixed and permeabilized in 70% ethanol for 20 min at −20 °C or fixed in 4% paraformaldehyde and permeabilized with 0.01% Triton-X for 2 minutes. Cells were incubated in TUNEL reaction mixture (Roche, Germany) at 37 °C for 1 h, washed three times with PBS and incubated in blocking solution for 30 min at room temperature. Cells were incubated in blocking solution for 30 min at room temperature and then in primary antibody (anti-HIV-p24 or isotype controls: both 1:50) overnight at 4 °C. Cells were washed several times with PBS at room temperature and incubated with phalloidin conjugated to Alexa Fluor 488 (Thermo-Fisher, Carlsbad, CA) to identify actin filaments and/or the appropriate secondary antibody conjugated to FITC (Sigma, St. Louis, MO) for 1 h at room temperature, followed by another wash in PBS for 1 h. Then, cells were mounted using anti-fade reagent with DAPI. Cells were examined by confocal microscopy using an A1 Nikon (Tokio, Japan) to quantify the total numbers of cells as well as TUNEL positive cells.
Western Blot Analysis
Samples were lysed with RIPA buffer (Cell Signaling, Beverly, MA) containing protease inhibitors (Cell Signaling, Danvers, MA), and 50–80 µg of protein were electrophoresed on a 4–20% polyacrylamide gel (Bio-Rad), and transferred to nitrocellulose membranes. Membranes were probed with the mitochondrial antibodies described and developed with HRP (see original blots in Supplemental Fig. 1). Densitometric analysis was performed using NIH ImageJ software. The original gels are presented in supplemental figure 1.
Human tissue sections
Human tissues were collected as part of the IRB-approved for Rutgers University and the Manhattan HIV Brain Bank and National NeuroAIDS Tissue Consortium (NNTC). Sections of 15 to 25 µm thickness were processed for immunofluorescence and confocal microscopy as described above (n = 11, four uninfected and five HIV-infected with no viral replication detected for 6–24 years, see Table 1 for details).
Table 1.
Patient number | HIV status | Age | Gender | ART Current ARVs (5 y of death) | CD4 counts (cells/mm) | Viral Load (copies/ml) | Years with HIV |
---|---|---|---|---|---|---|---|
1 | − | 42 | M | N.A. | N.D. | N.A. | N.A. |
2 | − | 45 | F | N.A. | N.D. | N.A. | N.A. |
3 | − | 38 | F | N.A. | N.D. | N.A. | N.A. |
4 | − | 42 | F | N.A. | N.A. | N.A. | N.A. |
5 | + | 31 | M | 3TC, D4T | 241 | 17226 | 24 y |
6 | + | 50 | F | CBV, KTA, TFV | 111 | <50 | 24 y |
7 | + | 41 | M | ATV, RTV, TRU | 228 | <50 | 11 y |
8 | + | 48 | M | ATV, DDI, TFV | 265 | 181 | 6 y |
9 | + | 48 | M | 3TC, EFV, TFV | 255 | <50 | 13 y |
Notes: M: male; F: Female; N.A.: not applicable; N.D.: not determined.
Anti-retrovirals: 3TC, lamivudine (Epivir); ATV, atazanavir (Reyataz); CBV, zidovudine + lamivudine (Combivir); DDI, didanosine (Videx); KTA, LPV/RTV; lopinavir/ritonavir (Kaletra); RTV, ritonavir (Norvir); TFV, TFV, PMPA; tenofivir DF (Viread); DRV, TMC-114, darunavir (Prezista); TRU, emtricitabine + tenofovir (Truvada).
Statistical analysis
Statistical analyses were used to determine the significance of data from all experiments. Significance was assessed by determining the validity of the null hypothesis that states that all treated groups were the same as their respective controls or HIV infection alone. Origin 8 software was used to test the null hypothesis by comparing the relative value to a theoretical mean of 1 using a two-tailed, two sample t-test with a 95% confidence intervale.
Electronic supplementary material
Acknowledgements
We would like to thank National NeuroAIDS Tissue Consortium (NNTC) for providing all human samples. The NNTC is made possible through funding from the NIMH and NINDS by the following grants: Manhattan HIV Brain Bank (MHBB): U24MH100931; Texas NeuroAIDS Research Center (TNRC): U24MH100930; National Neurological AIDS Bank (NNAB): U24MH100929; California NeuroAIDS Tissue Network (CNTN): U24MH100928; and Data Coordinating Center (DCC): U24MH100925. This work was funded by The National Institute of Mental Health grant, MH096625, the National Institute of Neurological Disorders and Stroke, NS105584, and PHRI funding (to E.A.E.).
Author Contributions
All authors contributed to perform the experiments, analyze the data and write the manuscript (Paul Castellano, Lisa Prevedel, and Eliseo Eugenin).
Competing Interests
The authors declare that they have no competing interests.
Footnotes
Paul Castellano, Lisa Prevedel and Eliseo A Eugenin contributed equally to this work.
Electronic supplementary material
Supplementary information accompanies this paper at 10.1038/s41598-017-12758-w.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Ostrowski MA, et al. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol. 1999;73:6430–6435. doi: 10.1128/jvi.73.8.6430-6435.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Chun TW, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–188. doi: 10.1038/387183a0. [DOI] [PubMed] [Google Scholar]
- 3.Philpott SM. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res. 2003;1:217–227. doi: 10.2174/1570162033485357. [DOI] [PubMed] [Google Scholar]
- 4.Groot F, Welsch S, Sattentau QJ. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood. 2008;111:4660–4663. doi: 10.1182/blood-2007-12-130070. [DOI] [PubMed] [Google Scholar]
- 5.Eugenin, E. A., Gaskill, P. J. & Berman, J. W. Tunneling nanotubes (TNT) are induced by HIV-infection of macrophages: a potential mechanism for intercellular HIV trafficking. Cell Immunol254, 142–148, doi:S0008-8749(08)00157-3 (2009). [DOI] [PMC free article] [PubMed]
- 6.Eugenin EA, Gaskill PJ, Berman JW. Tunneling nanotubes (TNT): A potential mechanism for intercellular HIV trafficking. Communicative & integrative biology. 2009;2:243–244. doi: 10.4161/cib.2.3.8165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–964. doi: 10.1038/nri1733. [DOI] [PubMed] [Google Scholar]
- 8.Bellingan GJ, Caldwell H, Howie SE, Dransfield I, Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol. 1996;157:2577–2585. [PubMed] [Google Scholar]
- 9.Murphy J, Summer R, Wilson AA, Kotton DN, Fine A. The prolonged life-span of alveolar macrophages. Am J Respir Cell Mol Biol. 2008;38:380–385. doi: 10.1165/rcmb.2007-0224RC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Lassmann H, Hickey WF. Radiation bone marrow chimeras as a tool to study microglia turnover in normal brain and inflammation. Clin Neuropathol. 1993;12:284–285. [PubMed] [Google Scholar]
- 11.Melnicoff MJ, Horan PK, Breslin EW, Morahan PS. Maintenance of peritoneal macrophages in the steady state. J Leukoc Biol. 1988;44:367–375. doi: 10.1002/jlb.44.5.367. [DOI] [PubMed] [Google Scholar]
- 12.Wong JK, Yukl SA. Tissue reservoirs of HIV. Curr Opin HIV AIDS. 2016;11:362–370. doi: 10.1097/COH.0000000000000293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Honeycutt JB, et al. Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest. 2016;126:1353–1366. doi: 10.1172/JCI84456. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Raposo G, et al. Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic. 2002;3:718–729. doi: 10.1034/j.1600-0854.2002.31004.x. [DOI] [PubMed] [Google Scholar]
- 15.Pelchen-Matthews A, Kramer B, Marsh M. Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol. 2003;162:443–455. doi: 10.1083/jcb.200304008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Arainga M, et al. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology. 2017;14:17. doi: 10.1186/s12977-017-0344-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Badley AD, Sainski A, Wightman F, Lewin SR. Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis. 2013;4:e718. doi: 10.1038/cddis.2013.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cummins NW, Badley AD. Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV. Cell Mol Life Sci. 2013;70:3355–3363. doi: 10.1007/s00018-012-1239-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Eugenin EA, et al. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci. 2006;26:1098–1106. doi: 10.1523/JNEUROSCI.3863-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Eugenin EA, Dyer G, Calderon TM, Berman JW. HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in NeuroAIDS. Glia. 2005;49:501–510. doi: 10.1002/glia.20137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Martinez, A. D., Eugenin, E. A., Branes, M. C., Bennett, M. V. & Saez, J. C. Identification of second messengers that induce expression of functional gap junctions in microglia cultured from newborn rats. Brain Res 943, 191–201, doi:S0006899302026215 [pii] (2002). [DOI] [PubMed]
- 22.Eugenin EA, et al. Microglia at brain stab wounds express connexin 43 and in vitro form functional gap junctions after treatment with interferon-gamma and tumor necrosis factor-alpha. Proc Natl Acad Sci USA. 2001;98:4190–4195. doi: 10.1073/pnas.051634298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Cihlar, T. & Fordyce, M. Current status and prospects of HIV treatment. Curr Opin Virol18, 50–56, doi:S1879-6257(16)30020-7 (2016). [DOI] [PubMed]
- 24.Cary DC, Fujinaga K, Peterlin BM. Molecular mechanisms of HIV latency. J Clin Invest. 2016;126:448–454. doi: 10.1172/JCI80565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Banga R, Procopio FA, Perreau M. Current approaches to assess HIV-1 persistence. Curr Opin HIV AIDS. 2016;11:424–431. doi: 10.1097/COH.0000000000000282. [DOI] [PubMed] [Google Scholar]
- 26.Costiniuk CT, Jenabian MA. HIV reservoir dynamics in the face of highly active antiretroviral therapy. AIDS Patient Care STDS. 2015;29:55–68. doi: 10.1089/apc.2014.0173. [DOI] [PubMed] [Google Scholar]
- 27.Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1:a007096. doi: 10.1101/cshperspect.a007096. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Avalos, C. R. et al. Quantitation of Productively Infected Monocytes and Macrophages of SIV-Infected Macaques. J Virol, doi:JVI.00290-16 (2016). [DOI] [PMC free article] [PubMed]
- 29.Arainga M, Su H, Poluektova LY, Gorantla S, Gendelman HE. HIV-1 cellular and tissue replication patterns in infected humanized mice. Sci Rep. 2016;6:23513. doi: 10.1038/srep23513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Williams, D. W. et al. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res12, 85–96, doi:CHIVR-EPUB-60663 (2014). [DOI] [PMC free article] [PubMed]
- 31.Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology. 2009;6:51. doi: 10.1186/1742-4690-6-51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Carter GC, et al. HIV entry in macrophages is dependent on intact lipid rafts. Virology. 2009;386:192–202. doi: 10.1016/j.virol.2008.12.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol. 2008;62:425–443. doi: 10.1146/annurev.micro.62.081307.162758. [DOI] [PubMed] [Google Scholar]
- 34.Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69–81. doi: 10.1038/nri1527. [DOI] [PubMed] [Google Scholar]
- 35.Calantone N, et al. Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity. 2014;41:493–502. doi: 10.1016/j.immuni.2014.08.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Baxter AE, et al. Macrophage infection via selective capture of HIV-1-infected CD4+T cells. Cell Host Microbe. 2014;16:711–721. doi: 10.1016/j.chom.2014.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Welsch S, et al. HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog. 2007;3:e36. doi: 10.1371/journal.ppat.0030036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Waki K, Freed EO. Macrophages and Cell-Cell Spread of HIV-1. Viruses. 2010;2:1603–1620. doi: 10.3390/v2081603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Symeonides M, et al. HIV-1-Induced Small T Cell Syncytia Can Transfer Virus Particles to Target Cells through Transient Contacts. Viruses. 2015;7:6590–6603. doi: 10.3390/v7122959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hornik TC, Neniskyte U, Brown GC. Inflammation induces multinucleation of Microglia via PKC inhibition of cytokinesis, generating highly phagocytic multinucleated giant cells. J Neurochem. 2014;128:650–661. doi: 10.1111/jnc.12477. [DOI] [PubMed] [Google Scholar]
- 41.Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev. 2013;254:102–113. doi: 10.1111/imr.12068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Verollet C, et al. HIV-1 Nef triggers macrophage fusion in a p61Hck- and protease-dependent manner. J Immunol. 2010;184:7030–7039. doi: 10.4049/jimmunol.0903345. [DOI] [PubMed] [Google Scholar]
- 43.Gupta N, Gupta R, Rajwanshi A, Bakshi J. Multinucleated giant cells in HIV-associated benign lymphoepithelial cyst-like lesions of the parotid gland on FNAC. Diagn Cytopathol. 2009;37:203–204. doi: 10.1002/dc.20991. [DOI] [PubMed] [Google Scholar]
- 44.McNally AK, Anderson JM. Multinucleated giant cell formation exhibits features of phagocytosis with participation of the endoplasmic reticulum. Exp Mol Pathol. 2005;79:126–135. doi: 10.1016/j.yexmp.2005.06.008. [DOI] [PubMed] [Google Scholar]
- 45.Rengstl B, et al. Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells. Proc Natl Acad Sci USA. 2013;110:20729–20734. doi: 10.1073/pnas.1312509110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Han X, et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem. 2000;275:37984–37992. doi: 10.1074/jbc.M002334200. [DOI] [PubMed] [Google Scholar]
- 47.Ha B, et al. ‘Clustering’ SIRPalpha into the plasma membrane lipid microdomains is required for activated monocytes and macrophages to mediate effective cell surface interactions with CD47. PloS one. 2013;8:e77615. doi: 10.1371/journal.pone.0077615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Aguilar PS, et al. Genetic basis of cell-cell fusion mechanisms. Trends Genet. 2013;29:427–437. doi: 10.1016/j.tig.2013.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Huerta L, et al. HIV-envelope-dependent cell-cell fusion: quantitative studies. ScientificWorldJournal. 2009;9:746–763. doi: 10.1100/tsw.2009.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Kilbride SM, Prehn JH. Central roles of apoptotic proteins in mitochondrial function. Oncogene. 2013;32:2703–2711. doi: 10.1038/onc.2012.348. [DOI] [PubMed] [Google Scholar]
- 51.Li P, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–489. doi: 10.1016/S0092-8674(00)80434-1. [DOI] [PubMed] [Google Scholar]
- 52.Orellana JA, et al. HIV increases the release of dickkopf-1 protein from human astrocytes by a Cx43 hemichannel-dependent mechanism. J Neurochem. 2013 doi: 10.1111/jnc.12492. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Eugenin EA, Berman JW. Cytochrome C dysregulation induced by HIV infection of astrocytes results in bystander apoptosis of uninfected astrocytes by an IP and Calcium dependent mechanism. J Neurochem. 2013 doi: 10.1111/jnc.12443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Caroppi, P., Sinibaldi, F., Fiorucci, L. & Santucci, R. Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein. Curr Med Chem 16, 4058–4065, doi:CMC - AbsEpub - 044 [pii] (2009). [DOI] [PubMed]
- 55.Boehning D, Patterson RL, Snyder SH. Apoptosis and calcium: new roles for cytochrome c and inositol 1,4,5-trisphosphate. Cell Cycle. 2004;3:252–254. doi: 10.4161/cc.3.3.705. [DOI] [PubMed] [Google Scholar]
- 56.Reed JC. Mechanisms of apoptosis. The American journal of pathology. 2000;157:1415–1430. doi: 10.1016/S0002-9440(10)64779-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta. 2004;1644:107–113. doi: 10.1016/j.bbamcr.2003.10.016. [DOI] [PubMed] [Google Scholar]
- 58.Kim M, et al. A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nat Protoc. 2014;9:2755–2770. doi: 10.1038/nprot.2014.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Hansjee N, et al. Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes. J Acquir Immune Defic Syndr. 2004;36:671–677. doi: 10.1097/00126334-200406010-00003. [DOI] [PubMed] [Google Scholar]
- 60.Matteucci C, et al. Effector caspase activation, in the absence of a conspicuous apoptosis induction, in mononuclear cells treated with azidothymidine. Pharmacol Res. 2009;59:125–133. doi: 10.1016/j.phrs.2008.11.003. [DOI] [PubMed] [Google Scholar]
- 61.Peraire J, et al. HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors. Curr HIV Res. 2007;5:467–473. doi: 10.2174/157016207781662452. [DOI] [PubMed] [Google Scholar]
- 62.Adachi M, Zhao X, Imai K. Nomenclature of dynein light chain-linked BH3-only protein Bim isoforms. Cell Death Differ. 2005;12:192–193. doi: 10.1038/sj.cdd.4401529. [DOI] [PubMed] [Google Scholar]
- 63.Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–1132. doi: 10.1158/1078-0432.CCR-08-0144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Luo S, et al. Bim inhibits autophagy by recruiting Beclin 1 to microtubules. Mol Cell. 2012;47:359–370. doi: 10.1016/j.molcel.2012.05.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Budka H. Multinucleated giant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS) Acta Neuropathol. 1986;69:253–258. doi: 10.1007/BF00688301. [DOI] [PubMed] [Google Scholar]
- 66.Soontornniyomkij V, Wang G, Pittman CA, Wiley CA, Achim CL. Expression of brain-derived neurotrophic factor protein in activated microglia of human immunodeficiency virus type 1 encephalitis. Neuropathol Appl Neurobiol. 1998;24:453–460. doi: 10.1046/j.1365-2990.1998.00134.x. [DOI] [PubMed] [Google Scholar]
- 67.Orenstein JM. The Warthin-Finkeldey-type giant cell in HIV infection, what is it? Ultrastruct Pathol. 1998;22:293–303. doi: 10.3109/01913129809103350. [DOI] [PubMed] [Google Scholar]
- 68.Frankel SS, Wenig BM, Ferlito A. Human immunodeficiency virus-1 infection of the lymphoid tissues of Waldeyer’s ring. Ann Otol Rhinol Laryngol. 1997;106:611–618. doi: 10.1177/000348949710600716. [DOI] [PubMed] [Google Scholar]
- 69.Frankel SS, et al. Active replication of HIV-1 at the lymphoepithelial surface of the tonsil. Am J Pathol. 1997;151:89–96. [PMC free article] [PubMed] [Google Scholar]
- 70.Dargent JL, et al. HIV-associated multinucleated giant cells in lymphoid tissue of the Waldeyer’s ring: a detailed study. Mod Pathol. 2000;13:1293–1299. doi: 10.1038/modpathol.3880237. [DOI] [PubMed] [Google Scholar]
- 71.Vicandi B, et al. HIV-1 (p24)-positive multinucleated giant cells in HIV-associated lymphoepithelial lesion of the parotid gland. A report of two cases. Acta Cytol. 1999;43:247–251. doi: 10.1159/000330987. [DOI] [PubMed] [Google Scholar]
- 72.Lewin-Smith M, Wahl SM, Orenstein JM. Human immunodeficiency virus-rich multinucleated giant cells in the colon: a case report with transmission electron microscopy, immunohistochemistry, and in situ hybridization. Mod Pathol. 1999;12:75–81. [PubMed] [Google Scholar]
- 73.Garg H, Lee RT, Maurer-Stroh S, Joshi A. HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc. Virology. 2016;493:86–99. doi: 10.1016/j.virol.2016.03.010. [DOI] [PubMed] [Google Scholar]
- 74.Joshi A, et al. Genetic signatures of HIV-1 envelope-mediated bystander apoptosis. J Biol Chem. 2014;289:2497–2514. doi: 10.1074/jbc.M113.514018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Joshi A, Nyakeriga AM, Ravi R, Garg H. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity. J Biol Chem. 2011;286:36404–36413. doi: 10.1074/jbc.M111.281659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Perfettini JL, et al. Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ. 2005;12(Suppl 1):916–923. doi: 10.1038/sj.cdd.4401584. [DOI] [PubMed] [Google Scholar]
- 77.Lopez-Huertas MR, et al. The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem. 2013;288:7626–7644. doi: 10.1074/jbc.M112.408294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Coiras M, Lopez-Huertas MR, Alcami J. HIV-1 latency and eradication of long-term viral reservoirs. Discov Med. 2010;9:185–191. [PubMed] [Google Scholar]
- 79.Cummins NW, et al. Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. J Virol. 2016;90:4032–4048. doi: 10.1128/JVI.03179-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Sainski AM, et al. Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. J Cell Biol. 2014;206:867–876. doi: 10.1083/jcb.201405051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Wolf D, et al. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals. Nat Med. 2001;7:1217–1224. doi: 10.1038/nm1101-1217. [DOI] [PubMed] [Google Scholar]
- 82.Chen D, Wang M, Zhou S, Zhou Q. HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. Embo J. 2002;21:6801–6810. doi: 10.1093/emboj/cdf683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Cummins, N. W. et al. Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition. J Virol91, doi:10.1128/JVI.00012-17 (2017). [DOI] [PMC free article] [PubMed]
- 84.David D, et al. Involvement of Bcl-2 and IL-2R in HIV-positive patients whose CD4 cell counts fail to increase rapidly with highly active antiretroviral therapy. AIDS. 2002;16:1093–1101. doi: 10.1097/00002030-200205240-00002. [DOI] [PubMed] [Google Scholar]
- 85.Grelli S, et al. Apoptotic cell signaling in lymphocytes from HIV+ patients during successful therapy. Ann N Y Acad Sci. 2006;1090:130–137. doi: 10.1196/annals.1378.014. [DOI] [PubMed] [Google Scholar]
- 86.Yue FY, et al. Preferential apoptosis of HIV-1-specific CD4+ T cells. J Immunol. 2005;174:2196–2204. doi: 10.4049/jimmunol.174.4.2196. [DOI] [PubMed] [Google Scholar]
- 87.Eugenin EA, Berman JW. Cytochrome C dysregulation induced by HIV infection of astrocytes results in bystander apoptosis of uninfected astrocytes by an IP3 and calcium-dependent mechanism. J Neurochem. 2013;127:644–651. doi: 10.1111/jnc.12443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Eugenin EA, Berman JW. Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes. J Neurosci. 2007;27:12844–12850. doi: 10.1523/JNEUROSCI.4154-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Eugenin EA, et al. The role of gap junction channels during physiologic and pathologic conditions of the human central nervous system. J Neuroimmune Pharmacol. 2012;7:499–518. doi: 10.1007/s11481-012-9352-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Eugenin EA. Role of connexin/pannexin containing channels in infectious diseases. FEBS Lett. 2014;588:1389–1395. doi: 10.1016/j.febslet.2014.01.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Harada H, Grant S. Targeting the regulatory machinery of BIM for cancer therapy. Crit Rev Eukaryot Gene Expr. 2012;22:117–129. doi: 10.1615/CritRevEukarGeneExpr.v22.i2.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther. 2009;8:3173–3180. doi: 10.1158/1535-7163.MCT-09-0685. [DOI] [PubMed] [Google Scholar]
- 93.Sen S, et al. Role of hexokinase-1 in the survival of HIV-1-infected macrophages. Cell Cycle. 2015;14:980–989. doi: 10.1080/15384101.2015.1006971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Franzolin E, Salata C, Bianchi V, Rampazzo C. The Deoxynucleoside Triphosphate Triphosphohydrolase Activity of SAMHD1 Protein Contributes to the Mitochondrial DNA Depletion Associated with Genetic Deficiency of Deoxyguanosine Kinase. J Biol Chem. 2015;290:25986–25996. doi: 10.1074/jbc.M115.675082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Le Bras M, Rouy I, Brenner C. The modulation of inter-organelle cross-talk to control apoptosis. Med Chem. 2006;2:1–12. doi: 10.2174/157340606775197787. [DOI] [PubMed] [Google Scholar]
- 96.Babiker ZO, Wingfield T, Galloway J, Snowden N, Ustianowski A. Extreme elevation of ferritin and creatine kinase in primary infection with HIV-1. Int J STD AIDS. 2015;26:68–71. doi: 10.1177/0956462414531936. [DOI] [PubMed] [Google Scholar]
- 97.D’Aversa TG, Weidenheim KM, Berman JW. CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis. Am J Pathol. 2002;160:559–567. doi: 10.1016/S0002-9440(10)64875-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Liszewski MK, Yu JJ, O’Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods. 2009;47:254–260. doi: 10.1016/j.ymeth.2009.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.